Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasm Metastasis 30Prostatic Neoplasms 18Breast Neoplasms 17Lung Neoplasms 16Glioblastoma 16Carcinoma, Non-Small-Cell Lung 15Colorectal Neoplasms 14Pancreatic Neoplasms 12Multiple Myeloma 12Glioma 12Carcinoma, Renal Cell 10Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Astrocytoma 9Neoplasms 8Melanoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Gliosarcoma 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Carcinoma 6

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Magnetic Resonance Spectroscopy × Clear all
NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

Phase 1 Recruiting
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡